A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
72
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators